PHR
Get informed when a big investor buys or sells
+ FollowUndervalued by 208.1% based on the discounted cash flow analysis.
| Market cap | $609.47 Million |
|---|---|
| Enterprise Value | $666.88 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.04 |
| Beta | 0.89 |
| Outstanding Shares | 60,944,962 |
| P/E Ratio | 47.31 |
|---|---|
| PEG | -17.81 |
| Price to Sales | 1.21 |
| Price to Book Ratio | 1.93 |
| Enterprise Value to Revenue | 1.35 |
| Enterprise Value to EBIT | -735.26 |
| Enterprise Value to Net Income | -69 |
| Total Debt to Enterprise | 0.2 |
| Debt to Equity | 0.37 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.4684▼ 88.39% |
|---|---|
| Total Calls | 82,200▲ 41.24% |
| Total Puts | 285,100▲ 12.55% |
Holdings and activity of institutional investors.
| Ownership % | 98.22%▲ 0.80% |
|---|---|
| Total Invested | $495.21M▼ 49.53% |
| Investors Holding | 250▲ 16.00% |
No data
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients and provides a modern, convenient experience, while enabling our clients to optimi...
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy directly impact Phreesia's profitability, and its influence on Medicare pricing significantly affects the revenue and financial health of Phreesia's healthcare organization clients.
This committee directly regulates agencies like the FDA and influences labor laws. It drives the regulatory environment for Phreesia's core customer base (healthcare organizations) and potentially affects its own operations and staffing.
This committee has vast jurisdiction over interstate commerce, data privacy (FTC), and technology. As a SaaS platform handling patient data, Phreesia is directly impacted by regulations concerning data privacy, consumer protection, and general tech oversight.